The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 30 May 2006, www.theannals.com, DOI 10.1345/aph.1G408.
 The Annals of Pharmacotherapy: Vol. 40, No. 6, pp. 1024-1029. DOI 10.1345/aph.1G408
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boulanger, L.
Right arrow Articles by Menzin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boulanger, L.
Right arrow Articles by Menzin, J.

ANTICOAGULATION

Warfarin Exposure and the Risk of Thromboembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation

Luke Boulanger, MA

Director of Analytics, Boston Health Economics, Waltham, MA

Ole Hauch, MD

Director of Health Economics and Outcomes Research, AstraZeneca, LP, Wilmington, DE

Mark Friedman, MD

Medical Director, Boston Health Economics

Talia Foster, MS

Research Associate, Boston Health Economics

Deirdre Dixon, BS

Data Analyst, Boston Health Economics

Gail Wygant, RN MS

Director of Cardiovascular, Health Economics and Outcomes Research, AstraZeneca, LP

Joseph Menzin, PhD

President, Boston Health Economics

Reprints: Dr. Menzin, Boston Health Economics, 20 Fox Rd., Waltham, MA 02451-1007, fax 781/290-0029, jmenzin{at}bhei.com

BACKGROUND: Outcomes of anticoagulation have been assessed in commercially insured populations, but similar data do not exist for Medicaid populations.

OBJECTIVE: To assess the association between warfarin exposure and rates of thromboembolic and bleeding events among patients with nonvalvular atrial fibrillation (NVAF) enrolled in California Medicaid.

METHODS: Using a retrospective cohort design based on administrative claims data, we selected Medicaid enrollees aged 50 years and older based on their first claim with a diagnosis of AF between January 1, 1998, and March 31, 2002. Patients were excluded if they had selected contraindications to warfarin, claims for valve replacement procedures, or evidence that AF resulted from transient or reversible causes. Pharmacy claims and prothrombin time tests were used to define subsequent periods of warfarin use (exposure) and nonuse (nonexposure) by all patients. The relative rates of hospitalization for thromboembolic and bleeding events associated with periods of warfarin exposure versus nonexposure were estimated.

RESULTS: The 4355 study patients had a mean age of 74 years, and 65% were female. Fifty-nine percent filled any prescriptions for warfarin following AF diagnosis. Across all patients, warfarin exposure occurred during 37% of days after diagnosis. Thromboembolic events were 27% less frequent during periods of warfarin exposure relative to periods of non-exposure (p < 0.01). Major bleeding events were not significantly more common during periods of warfarin exposure (p = 0.55).

CONCLUSIONS: In this Medicaid population with NVAF, warfarin use was low and was associated with a relatively modest reduction in thromboembolic events, with no increase in major bleeding risk.

Key Words: atrial fibrillation, hemorrhage, thromboembolism, warfarin

Published Online, May 30, 2006. www.theannals.com, DOI 10.1345/aph.1G408




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.